Read More Healthcare Industry News ResMed (ASX: RMD) drops 8% as Astral recall clouds FY27 outlook ResMed fell 8% as FY27 sales guidance missed expectations. Astral recall costs and slower growth now test the ASX: RMD valuation. bySrinathAugust 9, 2026